Yatin Suneja's Stock Ratings

Guggenheim Analyst

Yatin Suneja is an analyst at Guggenheim. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/16/2024

Overall Average Return

-5.37%

Smart Score

49.8%

Overall Average Return Percentile

26th

Number of Ratings

73
Buy NowGet Alert
05/10/2024RAPTBuy Now
RAPT Therapeutics
$4.14——DowngradeBuy → NeutralGet Alert
05/02/2024NBIXBuy Now
Neurocrine Biosciences
$141.9119.79%$164 → $170MaintainsBuyGet Alert
04/29/2024ABVXBuy Now
Abivax
$13.80262.32% → $50Initiates → BuyGet Alert
02/27/2024CLDXBuy Now
Celldex Therapeutics
$39.94125.34%$72 → $90MaintainsBuyGet Alert
02/21/2024AXSMBuy Now
Axsome Therapeutics
$77.3561.6%$110 → $125MaintainsBuyGet Alert
01/02/2024LBPHBuy Now
Longboard Pharmaceuticals
$20.5156.02%$16 → $32MaintainsBuyGet Alert
12/22/2023KRTXBuy Now
Karuna Therapeutics
———DowngradeBuy → NeutralGet Alert
11/15/2023ROIVBuy Now
Roivant Sciences
$11.4240.11%$17 → $16MaintainsBuyGet Alert
11/15/2023MLTXBuy Now
MoonLake
$40.8688.45%$70 → $77MaintainsBuyGet Alert
10/31/2023TRMLBuy Now
Tourmaline Bio
$14.66241.16% → $50Initiates → BuyGet Alert
10/17/2023ROIVBuy Now
Roivant Sciences
$11.4248.86% → $17Initiates → BuyGet Alert
10/10/2023NMRABuy Now
Neumora Therapeutics
$9.63128.45% → $22Initiates → BuyGet Alert
09/22/2023SEELBuy Now
Seelos Therapeutics
$2.43——DowngradeBuy → NeutralGet Alert
09/22/2023IMVTBuy Now
Immunovant
$31.481.65% → $32ReiteratesBuy → BuyGet Alert
09/21/2023SEELBuy Now
Seelos Therapeutics
$2.43——DowngradeBuy → NeutralGet Alert
08/14/2023CABABuy Now
Cabaletta Bio
$12.62169.41% → $34ReiteratesBuy → BuyGet Alert
07/28/2023ARGXBuy Now
argenx
$376.6056.66%$545 → $590MaintainsBuyGet Alert
07/18/2023ARGXBuy Now
argenx
$376.6044.72%$505 → $545MaintainsBuyGet Alert
07/18/2023CABABuy Now
Cabaletta Bio
$12.62169.41% → $34Initiates → BuyGet Alert
07/17/2023REGNBuy Now
Regeneron Pharmaceuticals
$967.98-7.02%$935 → $900MaintainsBuyGet Alert
07/17/2023BTAIBuy Now
BioXcel Therapeutics
$2.07——DowngradeBuy → NeutralGet Alert
06/26/2023MLTXBuy Now
MoonLake
$40.8659.08%$51 → $65MaintainsBuyGet Alert
06/22/2023ZURABuy Now
Zura Bio
$6.00233.33% → $20Initiates → BuyGet Alert
06/15/2023XENEBuy Now
Xenon Pharmaceuticals
$40.3421.47% → $49ReiteratesBuy → BuyGet Alert
06/15/2023AXSMBuy Now
Axsome Therapeutics
$77.3542.21% → $110ReiteratesBuy → BuyGet Alert
05/23/2023IMVTBuy Now
Immunovant
$31.481.65%$30 → $32MaintainsBuyGet Alert
05/18/2023EYPTBuy Now
EyePoint Pharmaceuticals
$12.52339.3%$52 → $55MaintainsBuyGet Alert
05/17/2023LRMRBuy Now
Larimar Therapeutics
$7.4388.43%$12 → $14MaintainsBuyGet Alert
05/12/2023ANABBuy Now
AnaptysBio
$25.4776.68%$44 → $45MaintainsBuyGet Alert
05/09/2023BTAIBuy Now
BioXcel Therapeutics
$2.072122.11%$50 → $46MaintainsBuyGet Alert

Recent Analyst Stock Rating News

Unveiling 4 Analyst Insights On Celldex Therapeutics
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
Analyst Ratings For Axsome Therapeutics
What Analysts Are Saying About Axsome Therapeutics Stock
What Analysts Are Saying About Axsome Therapeutics Stock
Assessing Roivant Sciences: Insights From 5 Financial Analysts
Biotech Is Back With Guggenheim Upgrade: What You Need To Know
Guggenheim Partners upgraded shares of Biogen Inc (NASDAQ: BIIB) to Buy, citing the company's potential for growth driven by its Alzheimer's disease (AD) and major depressive disorder (MDD) operations.
Why Seelos Therapeutics Is Moving Today
Seelos Therapeutics, Inc. (NASDAQ: SEEL) shares are trading higher after Guggenheim analyst Yatin Suneja initiated coverage on the stock with a Buy rating and announced an $8 price target.
Analyst On La Jolla's Hypotension Drug: We Expect Approval Next Year
Ariad Pharmaceuticals Expected To See Clinical Catalysts
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free